German President Christian Wulff visits Fresenius Medical Care dialysis clinic in Ulyanovsk, Russia

Bad Homburg, Germany – Christian Wulff, President of the Federal Republic of Germany, today experienced Fresenius Medical Care’s activities in the treatment of dialysis patients in Russia first-hand. During his current trip to Russia, Wulff visited a Fresenius Medical Care dialysis clinic in Ulyanovsk, about 700 kilometers east of Moscow. A 50-person delegation of businessmen, politicians and journalists joined the Federal President. The president took the opportunity to learn about the treatment of patients with chronic kidney failure and spoke with doctors, care personnel and patients. The clinic in Ulyanovsk is one of the 10 dialysis clinics the world’s leading provider of dialysis services and products now operates in Russia.

“The president’s visit is a major honor for our company as well as the clinic’s employees and management,” said Dr. Emanuele Gatti, chief executive officer for Europe, Latin America, Middle East and Africa as well as global chief strategist of Fresenius Medical Care. “At the same time, it highlights how important the close cooperation between German and Russian partners is to improving health care in this large country. There is still not enough capacity to treat all the dialysis patients in Russia. We expect the strong increase in the number of cases to continue in the
coming years. Our goal is to further expand our long-time presence in the country and to treat as many dialysis patients as possible at a supreme quality."

Fresenius Medical Care is the leading provider of dialysis products in Russia. In cooperation with the Russian pharmaceutical company Rester, Fresenius Medical Care has operated a production site for peritoneal dialysis solutions in Izhevsk, the capital of the Udmurt Republic, since 2008. The company also offers dialysis services for patients with chronic kidney failure in its 10 Russian clinics. Currently, more than 20,000 patients regularly receive life-sustaining renal replacement therapy in Russia.

Fresenius Medical Care first opened the Ulyanovsk clinic in 2007. It was the first of the company's own clinics in Russia. Currently, 281 patients receive hemodialysis and 61 peritoneal dialysis there. The clinic employs a team of 73, among them 10 doctors, including the head nephrologist, as well as 52 nurses and nurses' assistants. This year Fresenius Medical Care also started construction on a second dialysis clinic in another Ulyanovsk neighborhood. It should be complete in 2011.

Note for the media: Pictures related to this press release can be found in the internet under: http://tinyurl.com/fme-ulyanovsk

# # #

Fresenius Medical Care is the world's largest integrated provider of products and services for individuals undergoing dialysis because of chronic kidney failure, a condition that affects more than 1.89 million individuals worldwide. Through its network of 2,599 dialysis clinics in North America, Europe, Latin America, Asia-Pacific and Africa, Fresenius Medical Care provides dialysis treatment to 202,414 patients around the globe. Fresenius Medical Care also is the world's leading provider of dialysis products such as hemodialysis machines, dialyzers and related disposable products. Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME, FME3) and the New York Stock Exchange (FMS, FMS/P).

For more information about Fresenius Medical Care, visit the company's website at www.fmc-ag.com.

This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to certain factors, including changes in business, economic and competitive conditions, regulatory reforms, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care AG & Co. KGaA's reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care AG & Co. KGaA does not undertake any responsibility to update the forward-looking statements in this release.